News | April 26, 2024
Merck 1Q 2024 sales up 9% to US$ 15.8 billion
Sales reflect continued strong growth in oncology and vaccines
Sales reflect continued strong growth in oncology and vaccines
The approval adds to a list of products that Strides has approved in this therapeutic category through the PEPFAR pathway taking the total to 15 products
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
Man Industries (India) Limited has received a new export order of approximately Rs. 1,300 crores.
Two biopharmaceutical experts join SK bioscience to strengthen the future strategies
The ANDA was filed as 'First to File' submission on NCE-1 date.
Phase 2 study evaluating an investigational weekly oral combination treatment regimen of islatravir and Gilead Sciences’ lenacapavir to resume with lower dose of islatravir
Company creates Younger T Cells for fighting cancer using its NR2F6 technology
She joins Enveda from Gilead Sciences
The new Oncology CRO will aim to drive faster execution and higher quality trial outcomes for Oncology sponsors.
Subscribe To Our Newsletter & Stay Updated
